TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
2.370
-0.030 (-1.25%)
Jan 21, 2025, 4:00 PM EST - Market closed
TScan Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for TScan Therapeutics stock have an average target of 11.4, with a low estimate of 9.00 and a high estimate of 15. The average target predicts an increase of 381.01% from the current stock price of 2.37.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 11, 2024.
Analyst Ratings
The average analyst rating for TCRX stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +532.91% | Dec 11, 2024 |
| Needham | Needham | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +364.14% | Dec 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +532.91% | Nov 15, 2024 |
| Needham | Needham | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +364.14% | Nov 12, 2024 |
| Needham | Needham | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +364.14% | Nov 6, 2024 |
Financial Forecast
Revenue This Year
3.54M
from 21.05M
Decreased by -83.18%
Revenue Next Year
3.72M
from 3.54M
Increased by 5.14%
EPS This Year
-1.14
from -1.87
EPS Next Year
-1.20
from -1.14
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 5.3M | 10.5M | 22.1M | |||
| Avg | 3.5M | 3.7M | 8.1M | |||
| Low | 2.6M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -75.1% | 196.5% | 492.3% | |||
| Avg | -83.2% | 5.1% | 118.3% | |||
| Low | -87.4% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.13 | -1.06 | -1.02 | |||
| Avg | -1.14 | -1.20 | -1.38 | |||
| Low | -1.13 | -1.39 | -1.74 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.